Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 33.29 USD -1.16% Market Closed
Market Cap: 9.5B USD
Have any thoughts about
Exelixis Inc?
Write Note

Exelixis Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Exelixis Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Exelixis Inc
NASDAQ:EXEL
Gross Profit
$2B
CAGR 3-Years
18%
CAGR 5-Years
17%
CAGR 10-Years
58%
Abbvie Inc
NYSE:ABBV
Gross Profit
$37.3B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Gross Profit
$22B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Gross Profit
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Gross Profit
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Gross Profit
$12B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
17%
No Stocks Found

Exelixis Inc
Glance View

Market Cap
9.5B USD
Industry
Biotechnology
Economic Moat
Wide

Exelixis Inc., founded in 1994, embarked on its journey in the biotech sector with a sharp focus on genomics and drug discovery. This San Francisco-based biopharmaceutical company has firmly imprinted its name within the oncology space, thanks to its innovative research and development endeavors. One of the company's flagship achievements is the development and commercialization of cabozantinib, a compound used to treat various types of cancer. Marketed under the brand names like Cabometyx and Cometriq, cabozantinib targets tumor growth and angiogenesis, the process through which tumors develop their own blood supply. By honing in on these therapeutic areas, Exelixis capitalizes on its robust pipeline and partnerships with other healthcare stakeholders, thus carving out a niche in precision medicine. The company's business model primarily revolves around the development, commercialization, and strategic licensing of its drug candidates. Through extensive research and collaborative efforts, Exelixis not only advances its own proprietary medications but also licenses out their discoveries to maximize outreach and revenue potential. Revenue streams are generated through product sales, developmental milestones, and royalties, with significant investments poured back into research to fuel future innovation. In the intricate dance of biotech, Exelixis thrives on balancing the risk of high research costs with the lucrative potential of breakthrough cancer treatments, demonstrating a conscious strategy of leveraging scientific expertise into a commercially viable portfolio.

EXEL Intrinsic Value
29.2 USD
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Exelixis Inc's Gross Profit?
Gross Profit
2B USD

Based on the financial report for Sep 30, 2024, Exelixis Inc's Gross Profit amounts to 2B USD.

What is Exelixis Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
58%

Over the last year, the Gross Profit growth was 17%. The average annual Gross Profit growth rates for Exelixis Inc have been 18% over the past three years , 17% over the past five years , and 58% over the past ten years .

Back to Top